Nikkei 225
Astellas Pharma
Astellas Pharma is a top-tier Japanese drugmaker strong in urology and oncology with global reach. Nikkei 225 constituent. Baseline node ahead of value-chain research; promoted to a full node once AI question demand is observed.
4503.T Updated Jul 11, 2026 2 AI consumers
Annual return · 2026-07-10'21+12.2%'22+6.4%'23-6.9%'24-8.4%'25+48.7%YTD+1.4%
Money in ▸·
Astellas Pharma~¥1.6T
▸ Money out·
Financials & Segments
- Total revenue · ~¥1.6T (FY2024)
- Segments · Oncology · Urology and transplant · Other pharmaceuticals
Revenue from
No refined links yet.
Pays to
No refined links yet.